Pharmacodynamics of intravenous procainamide as used during acute electropharmacologic testing
dc.contributor.author | Morady, Fred | en_US |
dc.contributor.author | Kou, William H. | en_US |
dc.contributor.author | Schmaltz, Stephen P. | en_US |
dc.contributor.author | Annesley, Thomas M. | en_US |
dc.contributor.author | De Buitleir, Michael | en_US |
dc.contributor.author | Nelson, Steven D. | en_US |
dc.contributor.author | Kushner, Jeffrey A. | en_US |
dc.date.accessioned | 2006-04-07T20:28:10Z | |
dc.date.available | 2006-04-07T20:28:10Z | |
dc.date.issued | 1988-01-01 | en_US |
dc.identifier.citation | Morady, Fred, Kou, William H., Schmaltz, Stephen, Annesley, Thomas, De Buitleir, Michael, Nelson, Steven D., Kushner, Jeffrey A. (1988/01/01)."Pharmacodynamics of intravenous procainamide as used during acute electropharmacologic testing." The American Journal of Cardiology 61(1): 93-98. <http://hdl.handle.net/2027.42/27475> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6T10-4C76CDW-SV/2/0b2080dc613190649604670b088e6a91 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/27475 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3337024&dopt=citation | en_US |
dc.description.abstract | No previous studies have determined the pharmacodynamics of intravenous procainamide when administered in a dose of 15 mg/kg and at a rate of 50 mg/min, as is common practice during etectropharmacologic testing. In this study, 30 patients received procainamide in this fashion; the right ventricular effective refractory period and the QRS duration at a ventricular pacing rate of 120/minute were then determined every minute for 20 minutes. Ten patients received no maintenance infusion of procainamide (group A), 10 received a 4 [mu]g/min maintenance infusion (group B) and 10 received an 8 mg/min maintenance infusion (group C). Ten additional patients received no procainamide and served as control subjects (group D). The plasma procainamide concentration was measured at 1, 5, 10,15 and 20 minutes after the loading dose was administered. A stable plasma procainamide concentration was not present in group A, B, or C until 15 minutes after infusion of the loading dose. The effective refractory period and QRS duration increased compared with baseline at 1 minute, decreased between 1 and 10 minutes and then remained essentially unchanged between 10 and 20 minutes in all 3 treatment groups. Concentration-effect relation was linear in each treatment group. The plasma procainamide concentrations in group C were significantly greater than in group A; however, the effects on refractoriness and QRS duration were similar in both groups. These findings indicate that with a procainamide dosing method commonly used during electropharmacologic testing, the plasma procainamide concentration decreases significantly during the first 15 minutes after the loading dose is administered; the effects of procainamide on ventricular refractoriness and conduction parallel the changes in the plasma procainamide concentration; and an 8 mg/min maintenance infusion of procainamide results in higher plasma procainamide concentrations without an associated increase in ventricular refractoriness or slowing of conduction. | en_US |
dc.format.extent | 713152 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Pharmacodynamics of intravenous procainamide as used during acute electropharmacologic testing | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Cardiology, the Clinical Research Center and the Departments of Internal Medicine and Pathology, University of Michigan Medical Center, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Division of Cardiology, the Clinical Research Center and the Departments of Internal Medicine and Pathology, University of Michigan Medical Center, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Division of Cardiology, the Clinical Research Center and the Departments of Internal Medicine and Pathology, University of Michigan Medical Center, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Division of Cardiology, the Clinical Research Center and the Departments of Internal Medicine and Pathology, University of Michigan Medical Center, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | no department found | en_US |
dc.contributor.affiliationother | no department found | en_US |
dc.contributor.affiliationother | no department found | en_US |
dc.identifier.pmid | 3337024 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/27475/1/0000517.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0002-9149(88)91311-2 | en_US |
dc.identifier.source | The American Journal of Cardiology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.